The effect of chronic kidney disease on lipid metabolism

AbstractThe major cause of death among chronic kidney disease patients is cardiovascular diseases. Cardiovascular and kidney disease are interrelated and increase the severity of each other. Dyslipidemia is one the major causes of cardiovascular disease among chronic kidney disease patients along with diabetes and hypertension. The relationship between dyslipidemia and chronic kidney disease is reciprocal. Dyslipidemia is known to be a risk factor for chronic kidney disease and chronic kidney disease causes major alterations on lipoprotein profile, defined as the “dyslipidemic profile” of chronic kidney disease patients. Increased triglyceride, very low density lipoprotein and oxidized low density lipoprotein as well as decreased high density lipoprotein and changes in the composition of lipoproteins contribute to the “dyslipidemic profile.” Treatmen t strategies targeting the “dyslipidemic profile” of chronic kidney disease could contribute to prevent cardiovascular diseases. Current therapy is based on the patient kidney function and consist mainly of statins. This review focuses on the effects of chronic kidney disease on the lipoprotein profile and how this may impact novel therapeutic approaches to cardiovascular risk.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research

Related Links:

Conclusion Activation of the Nrf2-dependent antioxidant system plays an important role in cell defense against oxidative stress damage, whereas the insufficiency of the Nrf2 system is associated with multiple aspects of the genesis and progression of metabolic diseases, posing a great risk to the cardiovascular system (Figure 1). The systemic increase of Nrf2 activity by several activators may be beneficial in the treatment of metabolic diseases. In addition, selective upregulation of Nrf2 genes may represent a potential therapy in obesity, diabetes and atherosclerosis. Looking to the future, experimental research that el...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Abstract Lower extremity peripheral artery disease (PAD) affects 12% to 20% of Americans 60 years and older. The most significant risk factors for PAD are hyperlipidemia, hypertension, diabetes mellitus, chronic kidney disease, and smoking; the presence of three or more factors confers a 10-fold increase in PAD risk. Intermittent claudication is the hallmark of atherosclerotic lower extremity PAD, but only about 10% of patients with PAD experience intermittent claudication. A variety of leg symptoms that differ from classic claudication affects 50% of patients, and 40% have no leg symptoms at all. Current guidelin...
Source: American Family Physician - Category: Primary Care Authors: Tags: Am Fam Physician Source Type: research
Conclusion: It appears that intensive treatment of SBP may be harmful in the general population where all have access to routine healthcare as with the UK National Health Services, but could be beneficial in high-risk patients who are closely monitored.
Source: Journal of Hypertension - Category: Cardiology Tags: ORIGINAL PAPERS: Treatment Source Type: research
Abstract Total cardiovascular risk estimation using a system such as SCORE is recommended for adults>40years of age without evidence of cardiovascular disease, diabetes, chronic kidney disease, severe hypertension or familial hypercholesterolemia. Before treatment, a full lipid profile is recommended, fasting in French guidelines, fasting or non-fasting in European guidelines. LDL-C has to be used as the primary target for treatment. For patients with elevated triglycerides, non-HDL-C level is also recommended as the secondary goal for treatment. In patients at very high and high cardiovascular risk, LDL-C goal...
Source: Presse Medicale - Category: General Medicine Authors: Tags: Presse Med Source Type: research
CONCLUSION: Women with STEMI are less likely to receive invasive management, revascularisation, or preventive medication at discharge. The reasons for these persistent differences in care require investigation. PMID: 30025513 [PubMed - as supplied by publisher]
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
CONCLUSION: Validated data are of vital importance for health managers to monitor users. The population of this study is predominantly elderly, obese, requiring multi-professional care to slow the progression of the disease and decrease morbidity and mortality. PMID: 29927457 [PubMed - as supplied by publisher]
Source: Jornal Brasileiro de Nefrologia - Category: Urology & Nephrology Tags: J Bras Nefrol Source Type: research
ConclusionsFenofibrate is a safe drug when used as monotherapy. Physicians need to be aware of potentially serious adverse effects such as myopathy and rhabdomyolysis when it is co-administered with statins irrespective of dose. In patients with risk factors for muscle toxicity, such as hepatic impairment, renal insufficiency, diabetes, hypothyroidism and advanced age, CPK levels should be evaluated within 2  weeks and followed more closely. In addition, patients should be instructed to stop statin and fibrate treatment immediately and seek medical advice if significant muscle weakness or pain develops. CPK levels mus...
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
Randomized controlled trials (RCTs) are considered the gold-standard study design for comparative effectiveness research, which involves directly comparing the effectiveness of one treatment to another. Despite their many benefits, RCTs have important limitations that can reduce their utility for certain types of comparative effectiveness research and limit the external validity of their findings. For this reason, real-world evidence—data about outcomes in actual patients who are receiving a treatment in a usual care setting—is gaining traction as a key source of evidence for comparative effectiveness research....
Source: Health Affairs Blog - Category: Health Management Authors: Tags: Drugs and Medical Innovation chronic disease comparative effectiveness research efficacy-effectiveness gap health care innovation measuring care value randomized controlled trials real-world evidence Source Type: blogs
In this study, researchers put some numbers to the correlation, and improve on previous attempts to rule out wealth and other effects as significant contributing causes. A study finds that a Chinese policy is unintentionally causing people in northern China to live 3.1 years less than people in the south, due to air pollution concentrations that are 46 percent higher. These findings imply that every additional 10 micrograms per cubic meter of particulate matter pollution reduces life expectancy by 0.6 years. The elevated mortality is entirely due to an increase in cardiorespiratory deaths, indicating that air poll...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Conclusions: The novel finding of this study is that CIMT-plaque progression could be a good predictor of new-onset CVD in a general population.
Source: Hypertension - Category: Cardiology Authors: Tags: Poster Abstract Presentations Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Chronic Kidney Disease | Diabetes | Endocrinology | Heart | Hypertension | Statin Therapy | Urology & Nephrology